TCM
VTGN icon

TCG Crossover Management’s VistaGen Therapeutics VTGN Stock Holding History

TCG Crossover Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.53M Hold
2,676,580
– – 0.04% 49
2025
Q4 		$1.77M Hold
2,676,580
– – 0.06% 43
2025
Q3 		$9.5M Hold
2,676,580
– – 0.47% 33
2025
Q2 		$5.35M Hold
2,676,580
– – 0.61% 29
2025
Q1 		$6.69M Hold
2,676,580
– – 0.91% 29
2024
Q4 		$7.9M Hold
2,676,580
– – 0.77% 33
2024
Q3 		$8.06M Hold
2,676,580
– – 0.68% 27
2024
Q2 		$9.31M Hold
2,676,580
– – 0.97% 23
2024
Q1 		$14.1M Hold
2,676,580
– – 1.12% 25
2023
Q4 		$13.8M Buy
+2,676,580
New +$10.1M 1.53% 21

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

TCG Crossover Management's VTGN Position: Q1 2026 in Review

TCG Crossover Management held its VistaGen Therapeutics (VTGN) position steady in Q1 2026 at 2,676,580 shares worth $1.53M. The position accounts for 0.04% of the portfolio, ranked #49.

TCG Crossover Management first reported a position in VTGN in Q4 2023 and has held it in 10 quarters since. The position peaked at $14.1M in Q1 2024. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • TCG Crossover Management held 2,676,580 shares of VistaGen Therapeutics worth $1.53M as of Q1 2026.
  • TCG Crossover Management left its VistaGen Therapeutics share count unchanged in Q1 2026.
  • VistaGen Therapeutics made up 0.04% of TCG Crossover Management's portfolio in Q1 2026, its #49 holding.
  • TCG Crossover Management first reported a position in VistaGen Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • TCG Crossover Management's VistaGen Therapeutics position peaked at $14.1M in Q1 2024.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.